Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials

被引:2
作者
Shao, Yu-Yun [1 ,2 ,3 ]
Akhmetzhanov, Andrei R. [4 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Taiwan Univ, Grad Inst Oncol, Coll Med, Taipei, Taiwan
[3] Natl Taiwan Univ, Dept Med Oncol, Canc Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Coll Publ Hlth, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Publ Hlth, Global Hlth Program, Taipei, Taiwan
关键词
Demographics; Etiology; Hepatocellular carcinoma; Immunotherapy; Targeted therapy; Prognosis; OPEN-LABEL; SORAFENIB; PLUS; ATEZOLIZUMAB; BEVACIZUMAB; MANAGEMENT; SURVIVAL;
D O I
10.1159/000542576
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Immune checkpoint inhibitors (ICIs) are fundamental in treating advanced hepatocellular carcinoma (HCC). Considering previous reports implied varied responses among patient subgroups, such as patients with different hepatitis etiologies, we planned this meta-analysis to identify specific populations that might derive greater survival benefits from ICIs as a first-line treatment. Methods: We conducted a comprehensive search in PubMed and the Cochrane Library for phase III clinical trials comparing ICIs and multikinase inhibitors (MKIs) as first-line therapies for advanced HCC. We extracted and synthesized hazard ratios (HRs) for overall survival across different patient subgroups mainly using the random-effect model. Results: Our analysis included nine phase III trials involving ICIs, either alone or in combination with other treatments, compared with MKIs. The synthesized HRs for patients with hepatitis B virus, hepatitis C virus, and nonviral etiologies were 0.74, 0.77, and 0.86, respectively, showing no significant differences (p= 0.13). Such finding remained when we only analyzed clinical trials with positive results. HRs consistently favored ICIs across various demographics such as age, sex, geographic region, performance status, alpha-fetoprotein levels, and disease stage or extent. Notably, patients with extrahepatic spread showed a trend toward better outcomes (HR 0.73) compared to those without (HR 0.85, p= 0.07). Conclusion: The efficacy of ICIs as a first-line treatment for advanced HCC was consistent across diverse patient subgroups, regardless of hepatitis etiology or other demographic factors. These findings do not support using these characteristics to determine the use of ICI therapy in advanced HCC.
引用
收藏
页码:302 / 310
页数:9
相关论文
共 40 条
[1]  
Abou-Alfa GK, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100070, 10.1056/EVIDoa2100070]
[2]   The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [J].
Akinyemiju, Tomi ;
Abera, Semaw ;
Ahmed, Muktar ;
Alam, Noore ;
Alemayohu, Mulubirhan Assefa ;
Allen, Christine ;
Al-Raddadi, Rajaa ;
Alvis-Guzman, Nelson ;
Amoako, Yaw ;
Artaman, Al ;
Ayele, Tadesse Awoke ;
Barac, Aleksandra ;
Bensenor, Isabela ;
Berhane, Adugnaw ;
Bhutta, Zulfiqar ;
Castillo-Rivas, Jacqueline ;
Chitheer, Abdulaal ;
Choi, Jee-Young ;
Cowie, Benjamin ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dey, Subhojit ;
Dicker, Daniel ;
Phuc, Huyen ;
Ekwueme, Donatus U. ;
Zaki, Maysaa El Sayed ;
Fischer, Florian ;
Furst, Thomas ;
Hancock, Jamie ;
Hay, Simon I. ;
Hotez, Peter ;
Jee, Sun Ha ;
Kasaeian, Amir ;
Khader, Yousef ;
Khang, Young-Ho ;
Kumar, G. Anil ;
Kutz, Michael ;
Larson, Heidi ;
Lopez, Alan ;
Lunevicius, Raimundas ;
Malekzadeh, Reza ;
McAlinden, Colm ;
Meier, Toni ;
Mendoza, Walter ;
Mokdad, Ali ;
Moradi-Lakeh, Maziar ;
Nagel, Gabriele ;
Nguyen, Quyen ;
Nguyen, Grant ;
Ogbo, Felix .
JAMA ONCOLOGY, 2017, 3 (12) :1683-1691
[3]   How to perform a meta-analysis with R: a practical tutorial [J].
Balduzzi, Sara ;
Ruecker, Gerta ;
Schwarzer, Guido .
EVIDENCE-BASED MENTAL HEALTH, 2019, 22 (04) :153-160
[4]  
Breiman L, 2001, MACH LEARN, V45, P5, DOI [10.3322/caac.21834, 10.1186/s12859-018-2419-4, 10.1016/j.rineng.2025.104079]
[5]   Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].
Bruix, Jordi ;
Raoul, Jean-Luc ;
Sherman, Morris ;
Mazzaferro, Vincenzo ;
Bolondi, Luigi ;
Craxi, Antonio ;
Galle, Peter R. ;
Santoro, Armando ;
Beaugrand, Michel ;
Sangiovanni, Angelo ;
Porta, Camillo ;
Gerken, Guido ;
Marrero, Jorge A. ;
Nadel, Andrea ;
Shan, Michael ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Llovet, Josep M. .
JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829
[6]   Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years [J].
Chen, Ting-Chun ;
Hsiao, Shun-Wen ;
Chen, Yang-Yuan ;
Yen, Hsu-Heng ;
Su, Wei-Wen ;
Hsu, Yu-Chun ;
Huang, Siou-Ping ;
Su, Pei-Yuan .
SCIENTIFIC REPORTS, 2024, 14 (01)
[7]  
Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]
[8]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[9]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[10]  
European Society for Medical Oncology, ESMO C 2023 C CAL